Anticholinergic medication and dental caries status in middle-aged xerostomia patients-a retrospective study.

Cholinergic antagonist DMFT Dental caries Xerostomia

Journal

Journal of dental sciences

ISSN: 2213-8862

Titre abrégé: J Dent Sci

Pays: Netherlands

ID NLM: 101293181

Informations de publication

Date de publication:
Jul 2022

Historique:

received: 09 12 2021

revised: 16 12 2021

entrez: 5 7 2022

pubmed: 6 7 2022

medline: 6 7 2022

Statut: ppublish

Résumé

Xerostomia is the most frequent side effect of anticholinergic (AC) medications, which block the cholinergic neurotransmission of saliva secretion. As the most significant increase in AC medications' usage reported in middle-aged adults, we aimed to explore whether the level of exposure to AC medication show association with the severity of caries status of middle-aged individuals who complained about medication-induced xerostomia. Our retrospective study included 414 individuals (between 45 and 64 years) with self-reported xerostomia. We determined caries status by the Decayed, Missing, or Filled Teeth (DMFT) index and quantified the level of AC drug exposure by the AC Drug Scale (ADS), verified through electronic medication records. Statistical analyses were performed using chi-square and ANOVA tests. Covariates were age, gender, smoking, edentulism, comorbidities, polypharmacy, number, and the type of AC medications. In total, 54% of patients were taking five or more AC drugs. The mean number of anticholinergics was 5.41 (±3.44), most frequently antidepressants and antipsychotics, among all medications 10.63 (±5.79). Higher ADS scores were associated (p = 0.006) with a higher number of missing teeth. Multiple linear regression model showed that the number of AC medications, age, and smoking status are associated with DMFT (mean of 18.7 ± 8.96) scores. Caries status of middle-aged xerostomia patients was found to be reflective of the level of AC exposure from medications. Our finding emphasizes the importance of assessing AC medication burden in affected dental patients to improve clinical prevention strategies and guide interdisciplinary treatment plans.

Sections du résumé

Background/purpose UNASSIGNED

Materials and methods UNASSIGNED

Our retrospective study included 414 individuals (between 45 and 64 years) with self-reported xerostomia. We determined caries status by the Decayed, Missing, or Filled Teeth (DMFT) index and quantified the level of AC drug exposure by the AC Drug Scale (ADS), verified through electronic medication records. Statistical analyses were performed using chi-square and ANOVA tests. Covariates were age, gender, smoking, edentulism, comorbidities, polypharmacy, number, and the type of AC medications.

Results UNASSIGNED

In total, 54% of patients were taking five or more AC drugs. The mean number of anticholinergics was 5.41 (±3.44), most frequently antidepressants and antipsychotics, among all medications 10.63 (±5.79). Higher ADS scores were associated (p = 0.006) with a higher number of missing teeth. Multiple linear regression model showed that the number of AC medications, age, and smoking status are associated with DMFT (mean of 18.7 ± 8.96) scores.

Conclusion UNASSIGNED

Caries status of middle-aged xerostomia patients was found to be reflective of the level of AC exposure from medications. Our finding emphasizes the importance of assessing AC medication burden in affected dental patients to improve clinical prevention strategies and guide interdisciplinary treatment plans.

Identifiants

DOI: 10.1016/j.jds.2021.12.014 PMID: 35784170 PMC: PMC9236892

pubmed: 35784170

doi: 10.1016/j.jds.2021.12.014

pii: S1991-7902(21)00310-X

pmc: PMC9236892

doi:

Types de publication

Journal Article

Langues

eng

Pagination

1206-1211

Subventions

Organisme : NIDCR NIH HHS

ID : K23 DE031021

Pays : United States

Informations de copyright

Déclaration de conflit d'intérêts

The authors have no conflicts of interest relevant to this article.

Références

Am J Med. 2009 Dec;122(12):1142-1149.e1-2

pubmed: 19958893

Gerodontology. 2001 Jul;18(1):21-4

pubmed: 11813385

Oral Dis. 2003 Jul;9(4):165-76

pubmed: 12974516

J Public Health Dent. 2019 Dec;79(1):34-43

pubmed: 30440082

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1107-1115

pubmed: 30196250

Eur J Clin Pharmacol. 2013 Jul;69(7):1485-96

pubmed: 23529548

Postgrad Med J. 2014 Apr;90(1062):205-7

pubmed: 24643260

Am J Geriatr Pharmacother. 2006 Mar;4(1):42-51

pubmed: 16730620

Eur J Clin Pharmacol. 2021 Feb;77(2):147-162

pubmed: 33011824

Am J Geriatr Psychiatry. 2016 Dec;24(12):1189-1190

pubmed: 27769834

J Am Dent Assoc. 2008 May;139 Suppl:35S-40S

pubmed: 18460678

PLoS One. 2017 Feb 10;12(2):e0171353

pubmed: 28187171

JAMA. 2016 Oct 11;316(14):1464-1474

pubmed: 27727382

BMC Geriatr. 2015 Mar 25;15:31

pubmed: 25879993

NCHS Data Brief. 2010 Sep;(42):1-8

pubmed: 20854747

J Clin Pharmacol. 2006 Dec;46(12):1481-6

pubmed: 17101747

J Am Geriatr Soc. 2015 Nov;63(11):2227-46

pubmed: 26446832

Odontology. 2018 Oct;106(4):439-444

pubmed: 29356914

Health Qual Life Outcomes. 2006 Nov 08;4:86

pubmed: 17090332

Arch Intern Med. 2008 Mar 10;168(5):508-13

pubmed: 18332297

Lancet. 1981 Sep 26;2(8248):651-3

pubmed: 6116042

Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Dec;132(6):662-670

pubmed: 34593340

Dent Clin North Am. 2016 Apr;60(2):435-43

pubmed: 27040294

Gerodontology. 1997 Jul;14(1):33-47

pubmed: 9610301

Br J Clin Pharmacol. 2013 Mar;75(3):842-9

pubmed: 22924454

J Am Med Dir Assoc. 2018 Dec;19(12):1080-1085.e2

pubmed: 29983362

J Am Geriatr Soc. 2018 Jan;66(1):76-84

pubmed: 29071719

Drugs Aging. 2015 May;32(5):379-89

pubmed: 25832970

J Am Geriatr Soc. 2008 Jul;56(7):1333-41

pubmed: 18510583

J Am Dent Assoc. 2006 Aug;137(8):1151-9

pubmed: 16873333

Arch Oral Biol. 2001 May;46(5):413-23

pubmed: 11286806

Crit Rev Oral Biol Med. 1993;4(3-4):351-6

pubmed: 8373990

Gerodontology. 2018 Mar;35(1):3-10

pubmed: 28940566

Community Dent Oral Epidemiol. 2002 Jun;30(3):224-32

pubmed: 12000346